PF-5190457 is a potent and selective ghrelin receptor inverse agonist with a pKi of 8.36.
PF-5190457 has a superior balance of ghrelin receptor pharmacology and off-target selectivity[1].
PF-5190457 has excellent selectivity and demonstrates robust increases in glucose-stimulated insulin secretion in human whole and dispersed islets[1].
[1]. Bhattacharya SK, et al. Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate. ACS Med Chem Lett. 2014 Feb 24;5(5):474-9.
















